VBL Therapeutics Israeli Company
VBL has developed its Monocyte Targeting Technology (MTT), as an investigational new and specific way to limit chronic inflammation. Its program is based on the discovery of a novel target protein that is selectively expressed on the surface of monocytes and controls their ability to migrate (or 'walk' to) inflamed tissues. This protein is called MOSPD2 (the "mono-walk" receptor).
Health Tech & Life Sciences
Biotechnology
Genetics
Health Care
Medical
Therapeutics
Alternatives
No alternatives listed yet.
AI-Generated Alternatives
Powered by AI May contain mistakes
AI is thinking and generating alternatives...
Suggest an Alternative
Founders
Parent Companies/Investors
Office Locations
Modi'in-Maccabim-Re'ut, Israel
References
[1]
finder.startupnationcentral.org
- https://finder.startupnationcentral.org/company_page/vbl-therapeutics
[2]
crunchbase.com
- https://www.crunchbase.com/organization/vbl-therapeutics
External links are provided for reference and verification purposes.